- Home
- API vs SIGA Comparison
API vs SIGA Comparison
Compare API & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | API | SIGA |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.0M | 309.8M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | API | SIGA |
|---|---|---|
| Price | $3.98 | $3.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 398.3K | ★ 621.4K |
| Earning Date | 05-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $12.87 | $224.81 |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $3.42 |
| 52 Week High | $5.50 | $9.62 |
Technical Indicators
Market Signals| Indicator | API | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 29.52 |
| Support Level | $3.69 | N/A |
| Resistance Level | $4.06 | $4.84 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.96 | 3.57 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.